Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The karyotype of peripheral blood lymphocytes has been studied in a group of patients with Hodgkin's disease. Before any therapy, the karyotype was either normal or aneuploid. A few months after radiotherapy (total nodal irradiation) a conspicuous amount of structural chromosome aberrations was found. Three to six years after completion of radiotherapy, the lymphocyte karyotype was almost normal, even if stable ionizing radiation-induced aberrations were still detectable. This is consistent with the normal behaviour of these patients and with the long-lasting effect of radiations on nuclear D.N.A. Owing to the close relationship between ionizing raditions and chromosome aberrations on one hand, and abnormal karyotypes and tumors on the other, it cannot be overlooked that these aberrations may play an important role, together with other carcinogenic factors, in the development of second malignancies in these patients.
 ...
PMID:Chromosome radiation-induced aberrations in patients with Hodgkin's disease. Possible correlation with second malignancy? 65

One hundred twenty-seven patients with Hodgkin's disease, Stages III-IV, received total nodal irradiation. Of these, 101 patients were managed primarily by radiation therapy employing the split course sequential segmental radiation technique called the "3 & 2". A dose of 3800-4000 rad is delivered in 2 phases in an overall period of 12 to 13 weeks (TDF 61-64; 1094-1148 rets). For various reasons, the remaining 26 patients received their mantle irradiation to full doses 3800-4000 rad in 4 weeks (TDF 63-66; 1112-1184 rets) without rest periods and a few were irradiated after failing chemotherapy. Of the 101 patients treated between 1969-1974 using the "3 & 2" technique, 2 developed pericarditis (2.0%), none manifested symptomatic pneumonitis (0%), and 3 hypothyroidism )3.0%). The low incidence of severe complications is primarily the result of the technique employed to give total nodal irradiation. The overall incidence of Herpes Zoster was 42% (53/127), and there was a slightly higher incidence when TNI was given following splenectomy.
 ...
PMID:Complications of total nodal irradiation of Hodgkin's disease stages III and IV. 67 47

One hundred sixty-one patients with advanced Hodgkin's disease achieved complete remission after combination chemotherapy. Of these, 52 (32%) have subsequently relapsed and the patterns of relapse have been studied. The probability of relapse increases with increasing stage and particularly with the presence of systemic symptoms. Patients with Nodular Sclerosis histology are more likely to relapse than those with other histologies. Patients relapse primarily (92%) in sites of previous disease and particularly in nodal sites (75%). Nodal sites most frequently involved at relapse are the central nodal areas and the left supraclavicular area. When patients relapse in new sites they tend to be either adjacent to sites of previous disease which relapse or to be contiguous with previously involved sites of disease. In the small number of patients who received prophylactic radiation therapy to sites of nodal disease after complete remission, the pattern of relapse was not significantly altered.
 ...
PMID:Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy. 68 74

A case of nodulat sclerosing Hodgkin's disease in an elderly woman is presented. Following radiotherapy, widespread lymphomatous skin lesions developed anatomically unrelated to her nodal disease. These lesions have been controlled, but not eliminated by chemotherapy. Cutaneous manifestations of Hodgkin's disease are discussed including the possible pathologic mechanism in the present case. Skin involvement by Hodgkin's disease may follow a relatively benign course, provided disease elsewhere is treated appropriately.
 ...
PMID:Cutaneous Hodgkin's disease: indolent course and control with chemotherapy. 69 12

Eighty-two patients with advanced Hodgkin's disease who were in apparent complete remission (CR) after receiving 10 courses of combination chemotherapy were systematically reevaluated for persisting disease. Occult Hodgkin's disease was found in 10 (12%) of these patients and was predominantly present in nodal sites (91%) which were known to have been involved at initial staging (100%). Repeat chest radiography, Gallium-67 tumor scanning and lymphography were the most helpful procedures for detecting residual disease. Nine of the 72 (13%) patients felt to be free of disease after negative restaging subsequently relapsed within 8 months. Sites of early relapse, like the sites of disease found at restaging, occurred almost always in previously involved nodal areas. We conclude that systematic restaging should be incorporated into subsequent lymphoma trials in order to define more clearly complete remission and that every patient treated for lymphoma should undergo a careful restaging evaluation before therapy is discontinued.
 ...
PMID:Systematic restaging in patients with Hodgkin's disease: a Southwest Oncology Group Study. 70 42

Although staging laparotomy changes the stage of one third of patients with Hodgkin's disease, this change in stage does not establish that routine staging laparotomy is of clinical value. The value of laparotomy depends on the results of clinical decisions which are based on the information provided by laparotomy. Increased accuracy in staging may improve clinical results by eliminating undertreatment, with an increased risk of relapse, or overtreatment with an increased risk of morbidity--including second malignancies. In some clinical settings information provided by laparotomy may be clinically irrelevant. Since clinical studies have not established the optimal therapy for every stage of Hodgkin's disease, rigid guidelines for performing staging laporotomies cannot be established. However, staging laparotomy should be done only after consideration of how the information provided by laparotomy will affect clinical decisions. Recent evidence that the extent of abdominal nodal involvement has major prognostic implications may play a role in this decision-making process.
 ...
PMID:Staging laparotomy in Hodgkin's disease: a critical appraisal of its value. 72 35

Retrospective analysis of 405 patients suggested the clinical relevance of the Kiel classification of non-Hodgkin's lymphomas. In order to further clarify the clinical and prognostic features of the lymphoma entities diagnosed according to this histopathologic scheme, a prospective multicentric study was initiated by the Kiel Lymphoma Group. Initial staging evaluation is performed according to the Ann Arbor classification. On the basis of the hypothesis that like Hodgkin's disease non-Hodgkin's lymphomas originate, at least in part, as localized nodal or extranodal tumors, extended field irradiation is performed in localized disease (stages I and II) (with the exception of lymphoblastic lymphoma in children and young adults) whereas in more widespread disease (stages III and IV) (with the exception of stage III of centroblastic-centrocytic lymphoma) chemotherapy with additional radiotherapy is applied.
 ...
PMID:Outline of a prospective multicentric study on the clinical significance of the Kiel classification of non-Hodgkin's lymphomas. 74 47

The chemotherapy in its systemic form should be reserved for advanced Hodgkin's disease, i.e. stages III B and IV, but it deserves consideration even for stage II B if B-symptoms are prominent. The following problems will be discussed: 1. Monotherapy or combination chemotherapy? 2. Simultaneous or sequential drug application in case of combined chemotherapy? 3. Continuous application or intermittent therapy? 4. Maintenance therapy or unmaintained remission? 5. Use of chemotherapy in early stages too? 6. Use of combined modality approach (chemo-/radiotherapy) with regard to the stage of the disease? Some combination chemotherapy regimens (MOPP, ABDV) as well as sequential drug application in case of treatment failures will be discussed . Hazards of a complete course of chemotherapy following total nodal irradiation or total nodal irradiation following such combination chemotherapy are mentioned. If the radiation dose is reduced, the combined modality approach might still improve results of treatment. Finally some new drugs in development for treatment of resistant disease are introduced.
 ...
PMID:[Chemotherapy in Hodgkin's disease (author's transl)]. 74 13

Sixty-three patients with Hodgkin's disease, in stages I or II, asymptomatic (A) or symptomatic (B), were diagnosed and followed at the Chaim Sheba Medical Center from 1969 to 1976. Only 14 were staged pathologically. Until 1971, the patients received mantle or "inverted Y" therapy only; thereafter, an extended field that included mantle, upper abdomen and spleen irradiation was given. Symptomatic patients, as well as patients with extranodal involvement, received MOPP chemotherapy (nitrogen mustard, vincristine, procarbazine and prednisone) after termination of radiotherapy. Of 51 patients who were in stage IA or IIA, six relapsed 20 to 43 months after irradiation. Three had a pelvic recurrence; two of them were surgically staged. Thus, in only 1 of 51 patients could staging laparotomy possibly have detected pelvic disease and resulted in different therapy. Our results suggest that total nodal irradiation and staging laparotomy are not mandatory in stages IA and IIA of Hodgkin's disease. The group of 12 symptomatic patients is too small to allow us to draw definite conclusions as to the role of staging laparotomy and adjuvant chemotherapy. However, in view of the high relapse rate in the upstaged symptomatic patients, it seems that chemotherapy should be given to these patients.
 ...
PMID:Selective splenectomy in Hodgkin's disease, stages I and II. Results of treatment. 74 41

Blast cell surface markers for T- and B-lymphocyte characteristics were studied at diagnosis in 73 children with non-Hodgkin's lymphoproliferative malignancies. Three distinctive groups of patients were identified on the basis of the analysis of blast cells for surface immunoglobulin (SIg), sheep erythrocyte (sE) rosette formation, and complement receptors, The seven group I patients had monoclonal IgM on their blast cells, morphologic features of Burkitt's lymphoma, abdominal masses, and very short survival. The 13 group II patients had receptors for sE, complement, or both on their blast cells, mediastinal or nodal masses, and short survival. The distinction between leukemia and lymphoma based on the presence of bone marrow involvement at diagnosis is not prognostically useful in this group of patients. The blast cells of group II patients could not be morphologically distinguished from those of the group III patients. The 53 groups III patients had SIG, sE, and complement negative blast cells and could be further subdivided on the basis of while blood cell count. The nine group IIIA patients (greater than 100.0 X 10(9)/liter) had in general short survival, while most of the 44 group IIIB patients (less than than 100.0 X 10(9)/liter) have remained in complete remission. Positive surface markers, mass lesions, male sex, and age of diagnosis less than 2 years of greater than or equal to 10 years appear to be interrelated factors indicating poor prognosis. Elevated while blood cell count is a prognostic indicator independent of surface marker analysis or presence of mass lesions.
 ...
PMID:Prognostic significance of surface marker analysis in childhood non-Hodgkin's lymphoproliferative malifnancies. 79 93


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>